BLISS GVS PHARMA LTD.



June 15, 2023

To

The Manager, Listing Department National Stock Exchange of India Ltd.

Plot no. C/1 G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai- 400 051 Symbol: **BLISSGVS** To

General Manager, Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001 Scrip Code: **506197**

Subject: Intimation about Closure of US FDA Inspection at Plot 11 of the Company

Ref.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to the information dated March 18, 2023, we hereby notify that the United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practice (GMP) at the Company's manufacturing unit at Plot No. 11, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Palghar, 401404, Maharashtra from Monday, March 13, 2023, to Friday, March 17, 2023.

Pursuant to above inspection by the United States Food and Drug Administration (US FDA), the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection through which the US FDA agency assigned the inspection classification of the facility as "Voluntary Action Indicated (VAI)".

Based on this inspection and the US FDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP).

Kindly take the above information on record.

Thanking You,

For Bliss GVS Pharma Limited

Aditi Bhatt Company Secretary

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com